Shares of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) recorded -14.48% loss during trading session on January 11th, 2019. The script traded as low as $0.195 and last traded at $0.20. 8.03 million shares changed exchanged hands during trading, an increase of 37.2% from the 30-day average session volume of 12.79M shares. The firm had previously closed at $0.23. The company has $289.34M outstanding shares, price-to-earnings-growth ratio of 1.38and a beta of 3.59. The company has a RSI of 46.96, ATR of 0.05 and a volatility of 16.01% this week. SGYP has a 52 week low price of $0.07 and a 52 week high price of $2.80.
Investors have identified the tech company Synergy Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 56.91M, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Synergy Pharmaceuticals Inc. (SGYP) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For SGYP, the company has in raw cash 45.65 million on their books with 157.93 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 0 total, with 907.67 million as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.
SGYP were able to record 89.27 million as free cash flow during the recently reported quarter of the year, this saw their quarterly net cash flow reduce by 91.34 million. In cash movements, the company had a total of 89.08 million as operating cash flow.
Potential earnings growth for Synergy Pharmaceuticals Inc. (SGYP)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Synergy Pharmaceuticals Inc. recorded a total of 11.11 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.55% coming in sequential stages and their sales for the third quarter reducing by -0.10%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 3.92 million trying to sell their products during the last quarter, with the result yielding a gross income of 7.18 million. This allows shareholders to hold on to 289.34M with the revenue now reading -140 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.15 cents a share).
Is the stock of SGYP attractive?
Having a look at the company’s valuation, the company is expected to record -0.22 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SGYP sounds very interesting.
0 out of 3 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Synergy Pharmaceuticals Inc. stock. 0 analysts has assigned a Sell rating on the SGYP stock. The 12-month mean consensus price target for the company’s shares has been set at $2.00.